Risk Stratification in HCC Patients with VWF-Ag Levels

Von Willebrand Factor Antigen serves as a non-invasive biomarker for clinically significant portal hypertension and predicts time to recurrence and overall survival in hepatocellular carcinoma patients undergoing liver resection. VWF-Ag levels higher than 291% identify a high-risk group with increased posthepatectomy liver failure incidence, while levels of 182% or lower indicate suitability for surgery. VWF-Ag shows similar predictiveness for posthepatectomy liver failure as indocyanine green clearance, offering simplified preoperative risk stratification for resectable HCC patients.